title: Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
abstract: Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.
authors.affiliation: University of Colorado School of Medicine, The University of Colorado Cancer Center and Children's Hospital Colorado, Aurora, Colorado, USA. stephen.hunger@childrenscolorado.org
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hunger
authors.forename: Mignon L
authors.initials: ML
authors.lastname: Loh
authors.forename: James A
authors.initials: JA
authors.lastname: Whitlock
authors.forename: Naomi J
authors.initials: NJ
authors.lastname: Winick
authors.forename: William L
authors.initials: WL
authors.lastname: Carroll
authors.forename: Meenakshi
authors.initials: M
authors.lastname: Devidas
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Raetz
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012106:Research; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents